๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Improvement of plasma endothelin-1 and nitric oxide in patients with systemic sclerosis by bosentan therapy

โœ Scribed by Kawashiri, Shin-ya; Ueki, Yukitaka; Terada, Kaoru; Yamasaki, Satoshi; Aoyagi, Kiyoshi; Kawakami, Atsushi

Book ID
121563988
Publisher
Springer
Year
2013
Tongue
English
Weight
129 KB
Volume
34
Category
Article
ISSN
0172-8172

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Improvement of vascular endothelial func
Improvement of vascular endothelial function using the oral endothelin receptor antagonist bosentan in patients with systemic sclerosis
โœ P. P. Sfikakis; C. Papamichael; K. S. Stamatelopoulos; D. Tousoulis; K. G. Fragi ๐Ÿ“‚ Article ๐Ÿ“… 2007 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 102 KB ๐Ÿ‘ 2 views

## Abstract ## Objective Increased endothelin activity may play a role in the pathogenesis of vascular injury, a primary feature of systemic sclerosis (SSc; scleroderma). Our goal was to test the hypothesis that treatment with the oral endothelin receptor antagonist bosentan might improve vascular

Digital ulcers in systemic sclerosis: Pr
Digital ulcers in systemic sclerosis: Prevention by treatment with bosentan, an oral endothelin receptor antagonist
โœ J. H. Korn; M. Mayes; M. Matucci Cerinic; M. Rainisio; J. Pope; E. Hachulla; E. ๐Ÿ“‚ Article ๐Ÿ“… 2004 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 146 KB ๐Ÿ‘ 2 views

## Abstract ## Objective Recurrent digital ulcers are a manifestation of vascular disease in patients with systemic sclerosis (SSc; scleroderma) and lead to pain, impaired function, and tissue loss. We investigated whether treatment with the endothelin receptor antagonist, bosentan, decreased the